- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | CAMP4 closes $50.1 million second tranche of private placement | 1 | Investing.com | ||
| Di | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| Di | CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement | 112 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 27.07. | CAMP4 receives Australian clearance for SYNGAP1 therapy trial | 3 | Investing.com | ||
| 27.07. | CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder | 246 | GlobeNewswire (Europe) | Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through... ► Artikel lesen | |
| 27.07. | Camp4 Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.07. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 19.06. | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 16.06. | Potenzial von CMP-002: JPMorgan stuft CAMP4 Therapeutics auf "Overweight" hoch | 10 | Investing.com Deutsch | ||
| 16.06. | JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential | 2 | Investing.com | ||
| 12.06. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Chardan initiates CAMP4 Therapeutics stock with buy rating | 2 | Investing.com | ||
| 21.05. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 14.05. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | CAMP4 reports positive preclinical seizure data for CMP-002 | 1 | Investing.com | ||
| 14.05. | CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder | 1 | GlobeNewswire (USA) | ||
| 08.05. | Camp4 Therapeutics GAAP EPS of -$0.32 misses by $0.11 | 2 | Seeking Alpha | ||
| 28.04. | CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation | - | GlobeNewswire (USA) | ||
| 17.04. | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 14.04. | Rodman & Renshaw stuft CAMP4 Therapeutics mit "Buy" ein und sieht 55 % Potenzial | 1 | Investing.com Deutsch |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,666 | -1,05 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| EDITAS MEDICINE | 2,550 | +2,41 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,236 | +0,98 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,168 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,833 | -3,48 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,340 | +3,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,000 | +2,52 % | DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum | ||
| CEL-SCI | 1,500 | +2,74 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| CYTOKINETICS | 66,28 | -0,12 % | Cytokinetics, Incorporated: Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update | MYQORZO- (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,098 | +0,27 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $13.6 million in Q2 2026, up 15% over Q1 - - Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer -... ► Artikel lesen | |
| CURIS | 3,405 | 0,00 % | Curis, Inc.: Curis Doses First Five Patients in TakeAim CLL Study | LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,929 | +0,83 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,294 | -5,13 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| FAETH THERAPEUTICS | 24,390 | 0,00 % | Sensei BioTherapeutics GAAP EPS of -$2.84 |
Das Unternehmen CAMP4 THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,24 % bei einem Aktienkurs von 4,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.